Patents by Inventor O. Michael Colvin

O. Michael Colvin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100104628
    Abstract: The present invention relates, in general, to neuroblastoma and, in particular, to a method of treating neuroblastoma tumors, including refractory neuroblastoma tumors. The invention also relates to compounds and compositions suitable for use in such a method.
    Type: Application
    Filed: March 28, 2008
    Publication date: April 29, 2010
    Applicant: Duke University
    Inventors: Susan M. Ludeman, Michael P. Gamcsik, Timothy A. Driscoll, James B. Springer, O. Michael Colvin, David J. Adams, Karel Base
  • Patent number: 6825206
    Abstract: Camptothecin compounds which are effective anti-tumor compounds are disclosed. These conjugates inhibit the enzyme topoisomerase I and enhance the stability of the topoisomerase I-DNA cleavable complex.
    Type: Grant
    Filed: November 16, 2000
    Date of Patent: November 30, 2004
    Assignees: Research Triangle Institute, Duke University, National Institutes of Health
    Inventors: Michael P. Gamcsik, David J. Adams, O. Michael Colvin, Monroe E. Wall, Mansukh C. Wani, Govindarajan Manikumar, Yves Pommier
  • Publication number: 20040023318
    Abstract: The present invention relates, in general, to stem cells, and in particular, to a method of isolating stem cells and to reagents suitable for use in such a method. The invention further relates to stem cell populations isolatable in accordance with the present method.
    Type: Application
    Filed: August 1, 2003
    Publication date: February 5, 2004
    Applicant: Duke University
    Inventors: Clayton A. Smith, O. Michael Colvin, Robert W. Storms, Susan M. Ludeman
  • Patent number: 6322815
    Abstract: Polymeric drug conjugates in controlled release matrices are provided which allow sustained concentrations of therapeutic agents within a treated area for a prolonged period. The polymeric drug conjugates hydrolytically degrade in the extracellular space in a controlled, pre-specified pattern, releasing active drug. The conjugates diffuse within the tissue reaching a greater distance from the matrix than free drug would, because of their reduced rate of clearance from the tissue via the capillary system.
    Type: Grant
    Filed: July 22, 1994
    Date of Patent: November 27, 2001
    Inventors: W. Mark Saltzman, O. Michael Colvin, Wenbin Dang, Susan Ludeman
  • Patent number: 5876956
    Abstract: Production of a stem cell enriched cell composition using essentially non-toxic methodology comprising contacting a cell mixture with a cell-permeable, fluorescent non-polar compound that reacts upon contact with intracellular enzyme aldehyde dehydrogenase or phosphokinase found substantially exclusively in stem cells so as to form a biocompatible fluorescent product that is polar and non-permeable to the membrane of the stem cells, and isolating the cells containing the marker by fluorescent cell sorting.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: March 2, 1999
    Assignee: Johns Hopkins University School of Medicine
    Inventors: Richard J. Jones, O. Michael Colvin, John Hilton, Saul Sharkis
  • Patent number: 5407925
    Abstract: A method of treating human tumors is provided in which tumors are regionally treated with a cytolytic, pre-activated, bifunctional alkylating agent, namely 4-hydroperoxycyclophosphamide. The treatment is effective against a variety of tumor types within the central nervous systems.
    Type: Grant
    Filed: November 6, 1991
    Date of Patent: April 18, 1995
    Assignees: The Johns Hopkins University, Duke University
    Inventors: Darell D. Bigner, Henry S. Friedman, O. Michael Colvin